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OBJECTIVES We evaluated the early and mid-term (18-month) clinical events in a consecutive series of
patients undergoing a nonstaged multiple saphenous vein grafting (SVG) intervention with
stents as compared with a single SVG stent procedure.
BACKGROUND Saphenous vein graft angioplasty has been limited by high rates of distal embolization,
myocardial infarction, restenosis and late mortality. It is unknown whether stenting of
multiple, different SVGs at the same setting is associated with higher risk.
METHODS We evaluated in-hospital and mid-term clinical outcomes (death, Q wave myocardial
infarction [MI] and repeat revascularization rates up to 18 months) in 70 consecutive patients
treated with coronary stents in 2 (93% of patients) or 3 SVGs, as compared with 649 patients
undergoing stenting of a single SVG between January 1, 1994 and December 31, 1997.
RESULTS Overall procedural success was obtained in 97% of patients with 2 or 3 SVGs and 97% of
patients with a single SVG (p 5 0.94). Procedural complications were also similar (2.8% for
multiple SVGs vs. 2.7% for a single SVG, p 5 0.94). There was a higher prevalence of
periprocedural non–Q wave MI (28% vs. 16%, p 5 0.009) in the multiple SVG group.
During follow-up (18 months), target lesion revascularization was 11% in multiple SVG and
15% in single SVG interventions (p 5 0.19), and repeat revascularization (calculated per
treated patient) was also similar for both groups (19% vs. 18%, p 5 0.94). There was no
difference in death (5.6% vs. 5.3%, p 5 0.92) and Q wave MI rate (4.3% vs. 2.9%, p 5 0.55)
after the multiple SVG intervention. Overall cardiac event-free survival was similar for both
groups (62% vs. 60%, p 5 0.75). The study was powered to detect a clinically meaningful
difference of 10% in mortality; smaller differences could not be evaluated on the basis of this
sample size.
CONCLUSIONS Simultaneous stenting of multiple SVGs in carefully selected patients has similar in-hospital
procedural success and major complications rates, as well as mid-term (18-month) clinical
outcomes, as compared with single SVG stenting. Thus, multiple SVG interventions using
stents may be a viable revascularization strategy for carefully selected patients and suitable
lesions in multiple SVG disease. (J Am Coll Cardiol 2000;35:389–97) © 2000 by the
American College of Cardiology
Coronary artery bypass graft surgery (CABG) with saphe-
nous vein grafts (SVGs) is limited over the long term by
graft failure or a combination of graft failure and progres-
sion of coronary atherosclerosis (1–8). Optimal manage-
ment of these patients remains a subject of debate. Repeat
operation may not be an ideal option owing to higher
morbidity and mortality as well as poorer outcomes as
compared with the first operation (9–11). Percutaneous
transluminal coronary angioplasty (PTCA) has been used as
an alternative to repeat CABG in selected patients with
myocardial ischemia and SVG disease (12). Several variables
have been associated with increased risk of complications
after angioplasty of SVG lesions (13–19), including old (.3
years), diffusely diseased and totally occluded grafts (13–19)
and grafts containing intraluminal thrombus with increased
lesion friability and propensity for distal embolization
(20,21). There is evidence from the randomized SAphenous
VEin De novo (SAVED) trial that stenting may improve
the results of catheter-based SVG interventions with a
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better clinical outcome of six months as compared with
PTCA (22). However, in most studies the number of grafts
treated has been limited to one procedure at a time, mainly
because of the disease being limited to one graft in most
patients and concern of increased risk, with simultaneous
treatment of several diseased SVGs.
To determine the clinical outcomes in patients with
multiple SVG stenting, we evaluated procedural success,
major in-hospital complications and mid-term (18-month)
clinical events in a consecutive series of patients undergoing
a nonstaged multiple SVG intervention with stents as
compared with a single SVG stent procedure.
METHODS
Patients and follow-up. The patient cohort includes a
consecutive series of 719 patients (1,147 SVG lesions),
found in the Cardiology Research Foundation Angioplasty
Database, treated with stents between January 1, 1994 and
December 31, 1997. A total of 499 patients underwent
“redo” CABG during the same period. Patients were di-
vided into two groups according to the number of treated
grafts (1 vs. 2 or 3 SVGs) during a single intervention.
Among patients with more than one treated graft, the vast
majority (65 [93%] of 70 patients) had a two-graft inter-
vention. All indications for stent use (elective use to improve
early procedural safety and to reduce late clinical events,
provisional use to treat a suboptimal primary device result or
urgent use to treat abrupt or threatened closure) are in-
cluded in this study. Baseline clinical demographic data and
in-hospital complications were confirmed by independent
hospital chart review. Angiographic success was defined as
,50% residual diameter stenosis with Thrombolysis in
Myocardial Infarction (TIMI) flow grade 3. Clinical success
was defined as angiographic success without in-hospital
complications (death, Q wave myocardial infarction [MI]),
emergent CABG). Emergent CABG was defined as
CABG performed within 24 h of the index percutaneous
procedure.
All patients underwent a pre- and postintervention 12-
lead electrocardiogram (ECG) to detect procedure-related
ischemic changes or the appearance of a new pathologic Q
wave on the surface electrogram, or both. Blood samples
were routinely acquired from all patients after the procedure
for creatine kinase, MB fraction (CK-MB) enzyme at 8 h
and 16 and 24 h (normal values 0 to 4 ng/ml). The diagnosis
of non–Q wave MI was based on CK-MB elevation $5
times the normal values in the absence of new pathologic Q
waves on postintervention ECGs. Clinical outcomes at 18
months were obtained by serial telephone interviews by
research nurses, and late clinical events (death, Q wave MI),
target lesion revascularization or any cardiac events (death,
Q wave MI, coronary angioplasty or CABG) were adjudi-
cated and corroborated by accompanying source documen-
tation. In addition to target lesion revascularization, repeat
revascularization is also reported per patient (as any repeat
revascularization) and includes all target lesion and target
vessel revascularizations for single and multiple SVG dis-
ease.
Stent techniques. After the initial balloon angioplasty or
ablative procedure, coronary stents were implanted over
0.014-in. extrasupport guide wires. All stents used during
the study period were included in the current analysis.
Adjunct balloon inflation (12 to 16 atm) was operator-
dependent after initial stent deployment, with the majority
of the operators tending to use lower pressures (12 atm) and
with proper apposition of the stent being confirmed by
intravascular ultrasound (IVUS). Optimal stent implanta-
tion was carefully monitored using an iterative technique
with prespecified IVUS end points in the majority of cases.
The pre- and post-stent anticoagulation regimens included
aspirin (325 mg daily) and ticlopidine (250 mg twice daily)
for one month, and additional low molecular weight heparin
(for two weeks) in particularly high risk subsets (e.g.,
thrombus-containing lesions and patients with $3 stents).
Patients with nonstent SVG procedures, left internal mam-
mary artery interventions and staged stent procedures were
excluded from the analysis.
Angiographic analysis. A random sample of 777 of 1,147
lesions was available for complete quantitative and qualita-
tive angiographic analyses. Standard morphologic criteria
were used for the identification of lesion location, length,
eccentricity, calcification and ulceration. Quantitative an-
giographic analysis was performed using selected end-
diastolic frames demonstrating the stenosis in its most
severe projection. Using the contrast-filled guiding catheter
as the calibration standard, reference and lesion minimal
lumen diameters were determined before and after the
intervention.
Statistics. Continuous variables are presented as the mean
value 6 SD. Categorical data are presented as percent
frequency and compared between the groups using chi-
square statistics. Survival curves were calculated and dis-
played using the SAS LIFETEST procedure. Wilcoxon
statistics were used for survival comparison between the two
groups (single SVG vs. multiple SVGs). The mean values of
Abbreviations and Acronyms
CABG 5 coronary artery bypass graft surgery
CK-MB 5 creatine kinase, MB fraction
ECG 5 electrocardiogram
IVUS 5 intravascular ultrasound
MI 5 myocardial infarction
OR 5 odds ratio
PTCA 5 percutaneous transluminal coronary
angioplasty
SAVED 5 SAphenous VEin De novo trial
SVG 5 saphenous vein graft
TIMI 5 Thrombolysis in Myocardial Infarction trial
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nominal data were compared using the unpaired Student t
test. A p value ,0.05 was accepted as statistically signifi-
cant.
RESULTS
Baseline demographic data. Table 1 lists the baseline
characteristics of all treated patients, distinguished accord-
ing to the number of SVGs treated (one vs. two or three).
Overall, patient demographic data were similar between the
two groups. The patient group represents a typical patient
cohort undergoing SVG stenting, with a high prevalence of
class III or IV unstable angina and relatively old SVGs (age
8.6 6 4.5 years). Before stent deployment, patients were
more often treated with balloons alone. Excimer laser
angioplasty was used in 18% and 21% of the patients with a
single SVG versus multiple SVGs, respectively (Table 2).
Overall, the types of stents used and the average number of
stents per lesion were similar between the groups, with the
majority of patients in both groups treated with the “biliary”
version of the Palmaz-Schatz stent. The number of stents
per patient was higher in the multiple SVG group (Table 2).
The number of provisional/planned versus urgent stents was
similar between the two groups (97% vs. 96% and 3% vs.
4%; p 5 NS).
Lesion characteristics. Table 3 lists the lesion location
data for the treated lesions, as well as qualitative and
quantitative measurements. By quantitative angiography,
the average pre- and post-treatment lesion morphologic and
quantitative reference and lesion measurements were similar
for both groups, except for angiographic procedural dissec-
tions, which were more prevalent in the single SVG group
(7.3% vs. 0.8%, p 5 0.006). Abrupt closure and “no-reflow”
Table 1. Baseline Characteristics of the Study Group
Single SVG Group
(n 5 649)
Multiple SVG Group
(n 5 70) p Value
Patient age (yrs) 67 6 9 69 6 9 0.07
Male gender 81% 74% 0.21
Unstable angina 78% 79% 0.80
Hypertension 64% 64% 0.97
Diabetes mellitus 30% 36% 0.30
Hypercholesterolemia 70% 63% 0.21
Previous MI 64% 70% 0.32
Graft age (yrs) 8.5 6 4.5 9.2 6 4.2 0.26
Previous angioplasty 44% 51% 0.26
Angina CCS, III/IV 65% 60% 0.50
LVEF class 41 6 13% 39 6 12% 0.27
Data are presented as the mean value 6 SD or percentage of patients.
CCS 5 Canadian Cardiovascular Society; LVEF 5 left ventricular ejection fraction; MI 5 myocardial infarction; SVG 5
saphenous vein graft.
Table 2. Interventional Procedures
Single SVG Group
(n 5 649)
Multiple SVG Group
(n 5 70) p Value
Procedure type (before stenting)
Balloon angioplasty 89% 90% 0.58
Excimer laser angioplasty 18% 21% 0.85
DCA 3.8% 2.8% 0.47
TEC 5.1% 2.2% 0.09
Thrombectomy 0.4% 0.6% 0.80
Type of stent
Biliary Palmaz (6Schatz) 55% 54% 0.77
Coronary Palmaz-Schatz 35% 35% 0.92
Wallstent 2.7% 1.7% 0.40
Other 6.8% 9.2% 0.14
No. of stents per lesion 1.2 6 0.5 1.3 6 0.5 0.68
No. of stents per patient 1.7 6 0.9 3.0 6 1.2 0.0001
Data are presented as the percentage of lesions or mean value 6 SD.
DCA 5 directional coronary atherectomy; SVG 5 saphenous vein graft; TEC 5 transluminal extraction-endarterectomy
catheter.
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phenomena rates were similar between the two groups
(Table 3).
Procedural results. Overall angiographic and procedural
success rates were high and similar between the two groups
(Table 4). Similarly, major in-hospital complications (death,
Q wave MI and emergent CABG) were similar between the
groups (2.7% for single SVG and 2.8% for multiple SVG
stenting, p 5 0.94). Likewise, the prevalence of in-hospital
repeat target vessel angioplasty and stent thrombosis was
similar between the two groups. However, the periproce-
dural non Q wave MI rate (defined as CK-MB $5 times
normal) was nearly doubled in the multiple SVG group
(28% vs. 16%, p 5 0.009). The use of glycoprotein IIb/IIIa
inhibitor (ReoPro) was 4% in the single SVG group versus
6.5% in the multiple SVG group (p 5 NS). A representative
case of multiple SVG stenting is shown in Figure 1.
Mid-term outcomes. Clinical follow-up at 18 months was
available in 695 (98%) of 712 patients with a single SVG
and in 69 (99%) of 70 patients with two or three SVGs
(Table 4). There was no difference in late mortality between
the groups (5.3% for one SVG vs. 5.6% for two or three
SVGs, p 5 0.92). The rate of Q wave MI was also similar
for multiple SVG versus single SVG stenting at follow-up
(4.3% vs. 2.9%, p 5 0.55). Overall target lesion revascular-
ization at 18 months was 15% for single SVG stenting
versus 11% for multiple SVG stenting (p 5 0.19). The two
groups were also similar in the requirement for repeat
CABG (3.3% vs. 2.2%, p 5 0.46) and repeat angioplasty
(12% vs. 9%, p 5 0.22). The rate of repeat revascularization
(calculated per treated patient), was also similar between the
two study groups (18% for one SVG vs. 19% for two or
three SVGs, p 5 0.94). Likewise, actuarial event-free
survival curves for any event during 18-month follow-up
(death, Q wave MI, angioplasty or CABG) were similar for
both groups (62% for one SVG vs. 59% for two or three
SVGs, p 5 0.75) (Fig. 2).
Multivariate analysis. Logistic regression analysis was
used to identify independent predictors of any cardiac event
(death, Q wave MI, angioplasty or CABG), target lesion
revascularization or any repeat revascularization after SVG
stenting (Table 5). Variables expected to predict outcome
included in the model were the number of treated grafts
Table 3. Qualitative and Quantitative Characteristics of Stented Lesions
Single SVG Group
(n 5 965)
Multiple SVG Group
(n 5 182) p Value
Lesion location
Ostial 19% 17% 0.41
Proximal 28% 29% 0.70
Mid 28% 28% 0.84
Distal 18% 18% 0.95
Anastomosis 7.0% 7.3%
Lesion characteristics (N 5 648) (N 5 129)
Restenotic 28% 25% 0.54
Calcium 1.8% 3.1% 0.32
Length (mm) 9.9 9.9 0.99
Length $20 mm 7.6% 8.5% 0.73
Ulceration 20% 15% 0.16
Eccentricity 55% 54% 0.94
Thrombus 13% 14% 0.84
Total occlusion 4.6% 3.1% 0.44
TIMI flow grade 0 or 1 4.6% 3.1% 0.44
Aneurysm 7.5% 5.9% 0.65
Procedural complications
Dissection $type C 7.3% 0.8% 0.006
Abrupt closure 1.0% 1.1% 0.85
No reflow/distal embolization 3.4% 0.9% 0.15
Quantitative measurements
Proximal reference MLD (mm) 3.4 6 0.7 3.4 6 0.6 0.55
Lesion MLD (mm)
Before procedure (mm) 1.1 6 0.6 1.3 6 0.7 ,0.001
Final, after stent (mm) 3.1 6 0.7 3.1 6 0.6 0.38
Lesion % diameter stenosis
Before procedure 68 6 17% 63 6 18% 0.003
Final, after stent 8.5 6 15% 7.9 6 14% 0.69
Data are presented as the percentage of lesions or mean value 6 SD.
MLD 5 minimal lumen diameter; SVG 5 saphenous vein graft; TIMI 5 Thrombolysis in Myocardial Infarction trial.
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(one vs. two or three), the number of stents implanted (one
or two vs. three or more), unstable angina, age, gender,
history of angioplasty, diabetes mellitus, left ventricular
ejection fraction, graft age, reference vessel diameter and
final percent diameter stenosis. The presence of diabetes
(odds ratio [OR] 1.69) and smaller reference vessel diameter
(OR 0.60) were more frequently associated with adverse
cardiac events during follow-up. History of angioplasty (OR
1.75), reference vessel diameter (OR 0.71) and final diam-
eter stenosis (OR 0.97) were found to be predictors of target
lesion revascularization. The predictors of any repeat revas-
cularization were previous angioplasty (OR 1.52) and ref-
erence vessel diameter (OR 0.58) (Table 5). The number of
treated vessels or stents implanted did not predict the
adverse cardiac events during follow-up.
DISCUSSION
This study shows that carefully selected patients undergoing
a multiple versus single SVG stent intervention have 1)
similar in-hospital success and major complications; 2) a
nearly doubled prevalence of periprocedural non–Q wave
MI (28% vs. 16%, p 5 0.009); and 3) similar mid-term
(18-month) cardiac events, target lesion revascularization
and any repeat revascularization rates, although longer
follow-up is required in this patient group. In this large
patient cohort we also identified independent predictors of
any event or repeat revascularization after stent interven-
tions in SVG disease; previous angioplasty, diabetes mellitus
and reference vessel diameter were associated with clinical
outcomes in our multivariate model. In none of these
analyses did the number of grafts treated or the number of
stents used predict adverse cardiac outcomes. Thus, multiple
stenting may be a viable therapeutic alternative to repeat
CABG in carefully selected patient candidates and suitable
lesions in multiple SVG disease.
Previous SVG angioplasty experiences. In a review of 16
contemporary PTCA series comprising 1,571 patients un-
dergoing SVG interventions (without stents), de Feyter et
al. (13) reported an overall 88% procedural success rate. In
aggregate, ischemic complications were infrequent and in-
cluded death (1%), MI (4%) and CABG (2%). Distal
embolization was reported to occur in 3% of patients.
Overall procedural success was slightly lower in lesions
involving the proximal versus mid or distal segments.
Higher rates of angiographic restenosis were noted in
proximal segments (58% vs. 52% and 28% in mid and distal
segments, respectively).
Previous SVG stent experiences. Urban et al. (23) sum-
marized their initial SVG Wallstent experiences in 13
patients; the procedure success rate was 100% with 20%
restenosis (77% follow-up). Piana et al. (24) and Fenton et
al. (25), in two different series, reported restenosis rates of
59% and 34%, respectively, after SVG stenting in single vein
Table 4. In-Hospital Procedural Results and Clinical Outcomes at 18-Month Follow-Up
Single SVG Group
(n 5 649)
Multiple SVG Group
(n 5 70) p Value
In-hospital results
Angiographic success 99% 98% 0.21
Procedural success 97% 97% 0.94
Death 1.3% 2.8% 0.29
Q wave MI 1.1% 0% 0.37
Emergent CABG 0.9% 0% 0.44
Major hospital complications 2.7% 2.8% 0.94
Non–Q wave MI 16% 28% 0.009
CK-MB $5 normal
CK-MB $3 normal 22% 33% 0.03
CK-MB $2 normal 28% 43% 0.01
Stent thrombosis 0.7% 0% 0.37
Repeat angioplasty 1.1% 1.5% 0.82
18-month follow-up
Death 5.3% 5.6% 0.92
Q wave MI 2.9% 4.3% 0.55
Target lesion revascularization
(PTCA 1 CABG)
15% 11% 0.19
Target lesion PTCA 12% 8.9% 0.22
Target lesion CABG 3.3% 2.2% 0.46
Any repeat revascularization 18% 19% 0.94
Cardiac event-free survival 62% 59% 0.75
Data are presented as percentage of patients.
CABG 5 coronary artery bypass graft surgery; CK-MB 5 creatine kinase, MB fraction; MI 5 myocardial infarction;
PTCA 5 percutaneous transluminal coronary angioplasty; SVG 5 saphenous vein graft.
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grafts. Revascularization rates at 15 months and 1 year were
39% and 23%, respectively. Eeckhout et al. (26) and de
Jaegere et al. (27) reported their experiences with the
Wallstent in SVGs and found restenosis rates of 18% and
53% and repeat revascularization rates of 32% and 43%,
respectively. De Jaegere et al. (27) concluded that stent
implantation in SVGs is acceptable, but the long-term
clinical outcome may be poor. However, in their study stent
implantation was reserved for patients with advanced graft
failure and did not include consecutive patients.
Subsequently, Wong et al. (28), in 1995, reported a large
series of 589 patients treated for SVG disease and demon-
strated a procedural success rate of 97%, with an overall
restenosis rate and event-free survival rate (at one year) of
30% and 76%, respectively. More recently, Goy and Eeck-
hout (29) reported a review of seven SVG stent series in
1,172 patients treated with 1,268 stents (average graft age
8.2 years). They reported an average death rate of 12% and
MI rate of 10% at two-year follow-up. Furthermore, the
restenosis rate ranged from 18% to 53% (mean 36%).
Event-free survival at two years was reported to range from
21% to 81% (mean 50%). The rate of target lesion revascu-
larization was reported to be 21%, with a total revascular-
ization rate of 36%. In most of these studies the Palmaz-
Schatz stent was used, although the Wallstent was used in
one study and a combination of the two stents was used in
an additional study.
Stent implantation versus angioplasty for SVGs. Brener
et al. (30) compared the one-year outcome of Palmaz-
Schatz stent implantation versus angioplasty for treatment
of obstructive lesions in SVGs. In-hospital composite end
points (death, MI and emergency CABG) were lower in the
stent group (10% vs. 17%, p 5 0.059), and adverse cardiac
events at one year were lower in the stent group (23% vs.
45%, p , 0.001).
In the recently reported prospective, randomized
SAVED trial (22), it was demonstrated that elective stent
implantation improves angiographic and clinical outcomes
as compared with balloon angioplasty in the treatment of
SVG disease. Stenting was associated with superior initial
angiographic results, higher rates of procedural success and
a trend toward fewer periprocedural non–Q wave MIs.
Figure 1. A, Before (arrow, left panel) and after (right panel)
stenting of the proximal SVG to the right coronary artery (RCA).
B, Before (arrow, left panel) and after (right panel) stenting of
the distal SVG to the RCA. C, Before (arrows, left panel) and
after (right panel) stenting of diffuse proximal disease in the SVG
to the left anterior descending coronary artery (LAD). D, Before
(arrows, left panel) and after (right panel) stenting of distal
disease in the SVG to the LAD, with excellent angiographic
results at both treatment sites. All four SVG lesions were in the
same patient and treated at the same intervention.
Figure 2. Actuarial event-free survival curves for any adverse event
(death, Q wave MI, PTCA or CABG) for 18 months after single
or multiple SVG stenting.
394 Bhargava et al. JACC Vol. 35, No. 2, 2000
Multiple Saphenous Vein Graft Stenting February 2000:389–97
Restenosis occurred in 37% of patients in the stent group
and 46% of patients in the PTCA group (p 5 0.24). The
composite outcome, in terms of freedom from death, MI
and CABG, was significantly better in the stent group (73%
vs. 58%, p 5 0.03). Laham et al. (31) compared multiple
native versus multiple SVG stenting in a small group of 33
and 51 patients, respectively. This study showed that death
and target site revascularization at one year was similar
between the two groups. This study has suggested that
multiple SVG stenting may be feasible and safe with
acceptable long-term outcomes.
Clinical significance. Over the past four study years, we
have performed multiple SVG stenting in selected patients,
some of whom had multiple previous CABGs (17% vs. 22%
in the single SVG group), which made percutaneous revas-
cularization an attractive strategy, when feasible, as com-
pared with “redo” CABG. The 97% procedural success rate
and 3% major complication rate underscore the high level of
reliability that stenting may offer in the treatment of vein
graft disease. The 18-month repeat revascularization rate of
19% and target lesion revascularization rate of 11% are
favorable for a subset of patients who characteristically have
a high (40% to 60%) restenosis rate and these rates are
below those seen in major stent trials.
Our study shows that multiple SVG interventions using
stents in carefully selected patients (primarily in patients
with two-graft disease) have similar in-hospital procedural
success and major complication rates. Angiographic proce-
dural dissections were higher in the single SVG group,
emphasizing that multivessel SVG stenting may have been
carried out successfully only when the first SVG results are
uneventful.
Distal embolization has been noted to be the primary
reason for CK-MB elevation in patients undergoing percu-
taneous interventions for SVG disease. Diffusely diseased
vein grafts with thrombus, ulceration and large eccentric
plaque volumes have been correlated with distal emboliza-
tion (32,33). Elevation of CK-MB after successful SVG
angioplasty, associated with increased late mortality, has
been previously reported by our group (34). That study
included patients with SVG disease undergoing all inter-
vention procedures. One-year mortality of 11.7% was dem-
onstrated in the CK-MB–elevated SVG group, which is
higher than that in the SVG stent groups reported in the
present study (5.3% and 5.6% for single and multiple SVG
stenting). However, the higher CK-MB elevations
(periprocedural non–Q wave MI rate of 28% vs. 16%) in the
multiple SVG group versus single SVG group did not
translate into differences in death, Q wave MI and overall
cardiac event-free survival at 18 months. This may empha-
size the role of stents in SVG disease. One should note,
however, that if in-hospital non–Q wave MI events had to
be included in the 18-month postintervention analysis, then
the overall MI rate would appear to be significantly higher
in the multiple SVG stent group during follow-up.
Study limitations. The primary limitation of our study is
that despite a large overall interventional volume included in
our analysis, the study might have been underpowered to
detect differences between the two groups. This is due to the
relatively small number of patients (n 5 70) included in the
multiple SVG group. According to power calculations we
find all the powers to be ,0.3 (i.e., type II error beta .0.7).
On the basis of the rates we found here and assuming a 9:1
ratio between the single versus multiple SVG patient
groups, the ability to detect significant differences in overall
major in-hospital complications and death would require
2,347,930 (2,113,137:234,793) and 503,660 (453,294:
50,366) patients, respectively, at an alpha level of 0.05 with
a power of 0.80. Because these numbers are so high, we can
say that it may be unrealistic to show a statistically signifi-
cant difference. This is a retrospective study to assess the
efficacy of stents in patients with multiple SVG disease and
especially its value as compared with “redo” CABG, as
systematic follow-up of these surgical patients is unavail-
able. It is an observational study emphasizing that multives-
sel SVG stenting may be performed successfully only when
Table 5. Independent Predictors of Any Cardiac Event, Target Lesion Revascularization and
Any Revascularization Rate During 18-Month Follow-Up
Predictive Variables Odds Ratio 95% Confidence Interval p Value
Any event
Diabetes mellitus 1.69 1.22–2.34 0.0015
Reference vessel diameter 0.60 0.46–0.79 0.0003
Target lesion revascularization
History of angioplasty 1.75 1.15–2.67 0.0089
Reference vessel diameter 0.71 0.52–0.98 0.0385
Final diameter stenosis 0.97 0.96–0.98 0.0003
Any repeat revascularization
History of angiopasty 1.52 1.04–2.22 0.0307
Reference vessel diameter 0.58 0.44–0.77 0.0002
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the first SVG results are uneventful, and it does not
compare staged, multiple SVG stenting with multiple SVG
stenting at the same setting. Second, the vast majority of our
patients had the intervention performed in two grafts, and a
quarter of the patients had left internal mammary artery
grafts as well (25% in the single SVG group vs. 28% in the
multiple SVG group). Therefore, the favorable results that
we report here are not necessarily applicable to a larger
group of patients with disease of three or more grafts. Third,
a selected patient group bias may have shown improved
results in multiple SVG stenting owing to the fact that the
multiple SVG intervention was undertaken only after the
primary lesion had been treated successfully. A similar bias
may be responsible for the tenfold increase in procedural
dissections in the single SVG group; furthermore, the
disease in the single SVG group was more severe. An
additional limitation may be the relatively infrequent use of
adjunctive glycoprotein IIb/IIIa inhibitor therapy during the
study period. Although the currently available data to
support the systematic use of the glycoprotein IIb/IIIa
inhibitor in SVG lesions are limited, it is possible that
additional procedural benefit might have been achieved with
more frequent use of this potent platelet-blocking drug, as
shown in recent angioplasty trials that mainly focused on
angioplasty procedures performed in native coronary arteries
(35,36). However, a subgroup analysis of 101 SVGs from
the Evaluation of IIb/IIIa platelet receptor antagonist 7E3
in Preventing Ischemic Complications (EPIC) trial dem-
onstrated that adjunctive abciximab administration reduced
the occurrence of distal embolization and non–Q wave MI
(37). This could have had a potential beneficial impact on
“major” CK-MB elevations that were frequently observed in
our study. The use of low molecular weight heparin during
the study period was largely empiric; we used it for complex
multiple SVG stenting, and other multiple stenting (38).
Finally, the current analysis does not include the use of long
Wallstents or newly designed covered stents, which may be
more suitable for the treatment of SVG stents. The status of
the left internal mammary artery has not been included in
the analysis, and its impact on outcome is unknown.
Conclusions. Unlike previous conventional angioplasty ex-
periences, multiple SVG interventions using stents in care-
fully selected patients (primarily in patients with two-graft
disease) have similar in-hospital procedural success and
major complication rates, as well as similar mid-term
(18-month) clinical outcomes (death, MI and repeat revas-
cularization rates). Thus, multiple SVG interventions using
stents may be a viable revascularization strategy for carefully
selected patients and suitable lesions in multiple SVG
disease.
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